| dbo:abstract |
Lutetium(177Lu)vipivotidtetraxetan (177Lu-PSMA-617) ist ein Arzneistoff aus der Gruppe der Radiotherapeutika. Unter dem Namen Pluvicto (Hersteller: Novartis) wurde er im März 2022 in den USA zugelassen zur Behandlung einer bestimmten Form von Prostatakrebs. (de) Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy. The most common adverse reactions include fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. Lutetium (177Lu) vipivotide tetraxetan is a radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium-177, with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium (177Lu) vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells. Lutetium (177Lu) vipivotide tetraxetan was approved for medical use in the United States in March 2022. In October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the approval of Pluvicto to treat prostate cancer in the European Union. (en) |
| dbo:alternativeName |
Pluvicto (en) |
| dbo:casNumber |
1703749-62-5 |
| dbo:class |
dbr:Radiopharmaceutical |
| dbo:drugbank |
DB16778 |
| dbo:fdaUniiCode |
G6UF363ECX |
| dbo:kegg |
D12335 |
| dbo:pubchem |
122706785 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/177Lu_vipivotide_tetraxetan_-177LU-PSMA-617.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/unii/G6UF363ECX |
| dbo:wikiPageID |
70381482 (xsd:integer) |
| dbo:wikiPageLength |
13040 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1117138350 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Priority_review dbc:Novartis_brands dbr:University_Hospital_Heidelberg dbr:Radioligand dbr:Radiopharmaceutical dbr:Endocyte dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Prostate-specific_membrane_antigen dbr:Prostate_cancer dbc:Radiopharmaceuticals dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Novartis dbr:German_Cancer_Research_Center dbc:Breakthrough_therapy dbc:Lutetium_complexes dbr:Lutetium-177 dbr:Intravenous |
| dbp:atcPrefix |
None (en) |
| dbp:casNumber |
1703749 (xsd:integer) |
| dbp:chemspiderid |
58828499 (xsd:integer) |
| dbp:class |
dbr:Radiopharmaceutical |
| dbp:dailymedid |
Pluvicto (en) |
| dbp:drugName |
Lutetium vipivotide tetraxetan (en) |
| dbp:drugbank |
DB16778 (en) |
| dbp:kegg |
D12335 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:pubchem |
122706785 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Intravenous |
| dbp:smiles |
[177Lu+3].OCCC[C@H]CO (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
RSTDSVVLNYFDHY-BGOLSCJMSA-K (en) |
| dbp:synonyms |
177 (xsd:integer) |
| dbp:tradename |
Pluvicto (en) |
| dbp:unii |
G6UF363ECX (en) |
| dbp:usan |
Lutetium Lu 177 vipivotide tetraxetan (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_American_English dbt:Use_dmy_dates dbt:Therapeutic_radiopharmaceuticals |
| dct:subject |
dbc:Novartis_brands dbc:Radiopharmaceuticals dbc:Breakthrough_therapy dbc:Lutetium_complexes |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Lutetium(177Lu)vipivotidtetraxetan (177Lu-PSMA-617) ist ein Arzneistoff aus der Gruppe der Radiotherapeutika. Unter dem Namen Pluvicto (Hersteller: Novartis) wurde er im März 2022 in den USA zugelassen zur Behandlung einer bestimmten Form von Prostatakrebs. (de) Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy. The most common adverse reactions include fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. Lutetium (177Lu) vipivotide tetraxetan was approved for medical use in the United States in March 2022. (en) |
| rdfs:label |
Lutetium(177Lu)vipivotidtetraxetan (de) Lutetium (177Lu) vipivotide tetraxetan (en) |
| owl:sameAs |
wikidata:Lutetium (177Lu) vipivotide tetraxetan dbpedia-de:Lutetium (177Lu) vipivotide tetraxetan https://global.dbpedia.org/id/GTmLC |
| prov:wasDerivedFrom |
wikipedia-en:Lutetium_(177Lu)_vipivotide_tetraxetan?oldid=1117138350&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/177Lu_vipivotide_tetraxetan_-177LU-PSMA-617.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Lutetium_(177Lu)_vipivotide_tetraxetan |
| foaf:name |
Lutetium (177Lu) vipivotide tetraxetan (en) |
| is dbo:wikiPageRedirects of |
dbr:Pluvicto dbr:Lutetium_(177lu)_vipivotide_tetraxetan dbr:Lu-PSMA-617 |
| is dbo:wikiPageWikiLink of |
dbr:Endocyte dbr:Pluvicto dbr:Lutetium_(177lu)_vipivotide_tetraxetan dbr:Novartis dbr:Lu-PSMA-617 |
| is foaf:primaryTopic of |
wikipedia-en:Lutetium_(177Lu)_vipivotide_tetraxetan |
